Watchlist

Watchlist
Alder BioPharmaceuticals, Inc. (ALDR)
Alder BioPharmaceuticals, Inc. (ALDR)
Alder Biopharmaceuticals Makes A Comeback
After seeing a sharp pullback in the second half of 2017, Alder Biopharmaceuticals ( ALDR ) has made a strong comeback in 2018. The stock posted gains of more than 23% in the month of January. With the company on track for a BLA submission for its lead product candidate, the momentum could con…
Biotech Forum Daily Digest For January 31st
I know how men in exile feed on dreams of hope . Aeschylus The rally in the biotech sector continued on Monday as Sanofi ( SNY ) made its second acquisition with a substantial premium over the past week. Tuesday brought some profit taking into focus, which seemed logi…
Your Daily Pharma Scoop: Abeona's EB-101 Granted RMAT Designation, Teva To Raise Debt, Pfizer Reports Results
Analysis of top Seeking Alpha coverage: Abeona Today we will discuss the update from Abeona Therapeutics ( ABEO ) with regard to its lead candidate EB-101. Abeona announced on Tuesday that the FDA granted the Regenerative Medicine Advanced Therapy ((RMAT)) designation to EB-101, the Com…
Your Daily Pharma Scoop: Sanofi To Acquire Ablynx, PTC Therapeutics Announces Data, Lutathera Approved
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss Sanofis ( SNY ) takeover offer for Belgian biotech Ablynx ( ABLYF ). Ablyx had earlier this month rejected a hostile takeover offer from Novo Nordisk ( NVO ), noting that euro 30.50 per share offer undervalued …
Alder prices upsized convertible debt offering
Alder BioPharmaceuticals (NASDAQ: ALDR ) prices its $250M (from $200M) offering of 2.50% convertible senior notes due 2025 at par. Underwriters have a 30-day option to purchase up to an additional $37.5M of the notes. More news on: Alder Biopharmaceuticals Inc., Healthcare stocks news, …
Aradigm, The Final Countdown - Or: Was The 'Negative' Vote A Red Herring?
I, like others, felt that frequency of exacerbations was the more important endpoint. And I think that was met. -- Randy Hawkins, Meeting of the Antimicrobial Drugs Advisory Committee, January 11, 2018 As I said, I wanted to vote in support of approval, but I recognize that…
Alder Biopharmaceuticals - Modeling The Risk/Reward
I wanted to take an impartial look at Alder Biopharmaceuticals (NASDAQ: ALDR ) and see if, at the current price of $17.85, and a market of $1.21 Billion, it makes sense to take a risk on the stock. Some would say investing in an early stage biotech stock is akin to gambling. I dont ne…
Game Plan For The Week - Cramer's Mad Money (1/12/18)
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, January 12. The market is roaring and all the 401(k) money is coming in. Even Facebook's (FB) decline was not enough to derail the market. On the other hand, good earnings from JPMorgan (JPM) set a …
Alder BioPharmaceuticals, Inc. (ALDR)